MDX Meldex

    RNS Number : 7133H
  Meldex International PLC
  07 November 2008
   

 For Immediate Release  7 November 2008


    Meldex International Plc ("Meldex " or "the Company")

    Director Share Dealing and Term Sheet


    London, UK, 7 November 2008: Meldex (AIM: MDX), the specialty pharma and healthcare company announces that Board Directors Helmut
Kerschbaumer and Klaus Kuehne, Interim CFO and COO respectively, have sold 4,042,593 shares at 7.5p on 6 November, 2008. The shares were
held by Melmed Holding AG and Sanguisan, and the remaining shareholding of Melmed Holding AG and Sanguisan is 16,998,546.

    The shares were sold to an institutional investor to raise approximately �300,000, which is to be lent back to the Company in the form
of a bridge loan.

    The Company has also signed a term sheet with an investment company to inject up to �3m by way of a debt facility to the Company.
Further details will be announced when the agreement is finalised.





    For further information:

    Buchanan Communications                     + 44 (0) 20 7466 5000
    Rebecca Skye Dietrich

    FinnCap, NOMAD                        + 44 (0) 20 7600 1658
    Clive Carver




    About Meldex International Plc
    Meldex International plc is an innovative specialty pharmaceutical and OTC product Company. Listed on London's AIM in May 2003, the
Company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic
alliances with several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch
mechanism for its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007. Melbrosin's focus is on consumer over
the counter health care products based on substances of natural and plant origin which are developed into consumer orientated brands then
scaled, produced and distributed by Melbrosin. The Melbrosin complements the prescription pharmaceutical sales and marketing business
created and expanded in 2006.

    The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners
using its proprietary XGELTM polymer technology. For further information please go to www.meldexinternational.com




This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RDSFKOKKBBDDBDK

Meldex (LSE:MDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Meldex (LSE:MDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024